The role of positron emission tomography scans in the management of the N-positive neck in head and neck squamous cell carcinoma after chemoradiotherapy

Laryngoscope

Volumn 116, Issue 6, 2006, Pages 855-858

  Brkovich, Victoria S ^a   Miller, Frank R ^a,b   Karnad, Anand B ^a   Hussey, David H ^b   McGuff, H Stan ^b   Otto, Randal A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Head and neck cancer; Positron emission tomography (PET); Squamous cell carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION ANALYSIS; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMAGING; LYMPH NODE METASTASIS; MALE; MINIMAL RESIDUAL DISEASE; NECK DISSECTION; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR LOCALIZATION; HEAD AND NECK TUMOR; LYMPH NODE; MIDDLE AGED; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; SCINTISCANNING;

AGED; CARCINOMA, SQUAMOUS CELL; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NECK DISSECTION; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 33745281913     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlg.0000214668.98592.d6     Document Type: Article

References (20)

1. Clayman GL, Johnson CJ, Morrison W, Ginsberg L, Lippman SM. The role of neck dissection after chemoradiotherapy for oropharyngeal cancer with advanced nodal disease. Arch Otolaryngol Head Neck Surg 2001;127:135-139.
2. Lavertu P, Aldelstein DJ, Saxton JP, et al. Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in respectable stage III and IV squamous cell head and neck cancer. Head Neck Surg 1997;19:559-566.
3. Leon X, Quer M, Orus C, et al. Treatment of neck nodes after induction chemotherapy in patients with primary advanced tumors. Eur Arch Otorhinolaryngol 2000;257:521-525.
4. Puc MM, Chrzanowski FA, Tran HS, et al. Preoperative chemotherapy sensitized radiation therapy for cervical metastasis in head and neck cancer. Arch Otolaryngol Head Neck Surg 2000;126:337-342.
5. Sanguineti G, Corvo R, Benasso M, et al. Management of the neck after alternating chemoradiotherapy for advanced head and neck cancer. Head Neck 1999;21:223-228.
6. Stenson KM, Haraf DJ, Pelzer H, et al. The role of cervical lymphadenectomy after concomitant chemoradiotherapy. Arch Otolaryngol Head Neck Surg 2000;126:950-956.
7. Weisman RA, Robbins KT. Management of the neck in patients with head and neck cancer treated by concurrent chemotherapy and radiation. Otolaryngol Clin North Am 1998;31:773-784.
8. Frank DK, Hu KS, Culliney BE, et al. Planned neck dissection after concomitant radiochemotherapy for advanced head and neck cancer. Laryngoscope 2005;115:1015-1020.
9. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-2098.
10. Velazquez RA, McGuff HS, Sycamore DS, Miller FR. The role of computed tomographic scans in the management of the N-positive neck in head and neck squamous cell carcinoma after chemoradiotherapy. Arch Otolaryngol Head Neck Surg 2004;130:74-77.
11. Zimmer LA, Snyderman C, Fukui MB, et al. The use of combined PET/CT for localizing recurrent head and neck cancer: the Pittsburgh experience. Ear Nose Throat J 2005;84:104-110.
12. Ware RE, Mathews JP, Hicks RJ, et al. Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual abnormality after definitive treatment for squamous cell carcinoma of the head and neck. Head Neck 2004;26:1008-1017.
13. Porceduu SV, Weih L, Jarmolowski E, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo) radiotherapy in head and neck cancer. Head Neck 2005;27:175-181.
14. Kovacs AF, Dobert N, Gaa J, et al. Positron emission tomography in combination with sentinel node biopsy reduces the rate of elective neck dissections in the treatment of oral and oropharyngeal cancer. J Clin Oncol 2004;22:3973-3980.
15. Miller FR, Hussey DH, Beeram M, et al. Positron emission tomography in the management of unknown primary head and neck carcinoma. Arch Otolaryngol Head Neck Surg 2005;131:626-629.
16. Ryan WR, Fee WE, Le QT, Pinto HA. Positron-emission tomography for surveillance of head neck cancer. Laryngoscope 2005;115:645-650.
17. Schroeder H, Yeung HWD, Gonen M, Kraus D, Larson SM. Head and neck cancer: clinical usefulness and accuracy of PET/CT fusion. Radiology 2004;231:65-72.
18. Goerres GW, von Schulthes GK, Steinart HC. Why most PET of lung and head-neck cancer will be PET/CT. J Nucl Med 2004;45(suppl 1): 66S-71S.
19. Yao M, Smith RB, Graham MM, et al. The role of FDG PET in management of neck metastases from head and neck cancer after definitive radiation treatment. Int J Radiat Biol Phys 2005;63:991-995.
20. Poreddue SV, Jarmoloski E, Hicks RJ, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after chemoradiotherapy in head and neck cancer. Head Neck 2005;27:175-181.